+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Laboratory and clinical studies on 6059-S in children



Laboratory and clinical studies on 6059-S in children



Japanese Journal of Antibiotics 34(5): 782-799



Laboratory and clinical studies were performed on 6059-S in the field of pediatrics, a new semi-synthetic 1-oxacephem antibiotic, and results were as follows. 1. MICs of 6059-S were compared with those of cefazolin (CEZ) and cefmetazole (CMZ) on 31 strains of S. aureus, 29 strains of E. coli, 30 strains of K. pneumoniae and 16 strains of P. aeruginosa. With the inoculum size of 10(8) cells/ml an 10(6) cells/ml, the peak of distribution of MICs were S. aureus 6.25, 3.13 micrograms/ml, E. coli 0.2, 0.1 micrograms/ml, K. pneumoniae 0.2, 0.05 micrograms/ml and P. aeruginosa 12.5, 6.25 micrograms/ml, respectively. MICs 6059-S against S. aureus was more less 2 to 3 tubes than CEZ and CMZ, but against E. coli and K. pneunoniae were more higher than 3 to 4 tubes than CEZ and CMZ. 2. The serum concentrations and urinary recovery rate of 6059-S were measured in 5 pediatric patients. 6059-S was given 20 mg/kg by an intravenous injection to 2 cases or a 30 minutes intravenous drip infusion to 3 cases. The mean concentration of the former were 64.3, 44.3, 26.8, 11.7 and 5.0 micrograms/ml at 0.5, 1, 2, 4 and 6 hours, and T 1/2 was 1.51 hours. The urinary recovery rates was 75.0% within 6 hours after the injections. The mean concentration of the latter were 65.3, 86.3, 63.0, 40.3, 17.8 and 8.9 micrograms/ml at 0.25, 0.5, 1, 2, 4 and 6 hours, and T 1/2 was 1.63 hours. The urinary recovery rates was 52.1% within 6 hours after the injection. 3. Eleven cases with acute pneumonia, 1 case with acute bronchitis, 3 cases with acute purulent tonsillitis, 1 case with acute purulent parotitis and 1 case subcutaneous abscess were treated with 6059-S by intravenous injection. All cases were above effective clinically. Five strains of H. influenzae, 3 strains of S. pneumoniae, 2 strains of S. pyogenes and 1 strain of S. aureus were eradicated in all strains. No clinical adverse reaction and abnormal laboratory findings were noted.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 043505348

Download citation: RISBibTeXText

PMID: 6457176


Related references

Laboratory and clinical studies of 6059-S in pediatric field. Japanese Journal of Antibiotics 34(5): 800-816, 1981

Clinical study on 6059-S in children. Japanese Journal of Antibiotics 34(5): 757-763, 1981

Clinical evaluation of 6059-S therapy in children. Japanese Journal of Antibiotics 34(4): 599-607, 1981

Experimental and clinical studies on 6059-S. Japanese Journal of Antibiotics 34(5): 764-781, 1981

Clinical studies on 6059-S for acute peritonitis. Clinical effect and tissue concentration. Japanese Journal of Antibiotics 34(4): 623-630, 1981

Clinical evaluation of 6059-S in children, particularly in the treatment of bacterial meningitis. Japanese Journal of Antibiotics 34(4): 587-598, 1981

Clinical studies on 6059-S for biliary tract diseases. Clinical effect and tissue concentration. Japanese Journal of Antibiotics 34(4): 631-640, 1981

Clinical studies on 6059-S in pediatric field. Japanese Journal of Antibiotics 34(4): 558-561, 1981

Clinical studies of 6059-S in the field of pediatrics. Japanese Journal of Antibiotics 34(4): 608-617, 1981

Clinical studies on 6059-S in the field of pediatrics. Japanese Journal of Antibiotics 34(4): 551-557, 1981

Bacteriological and clinical studies of 6059-S in pediatric infections. Japanese Journal of Antibiotics 34(5): 747-756, 1981

Fundamental and clinical studies in pediatric field on 6059-S. Japanese Journal of Antibiotics 34(4): 562-575, 1981

Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation. Antimicrobial Agents and ChemoTherapy 17(3): 302-312, 1980

Cephaloridine: clinical and laboratory studies in children. Journal of Pediatrics 73(2): 255-261, 1968